Skip to main content

Table 4 Patients without ECMO compared to those with ECMO

From: Predictive ability of viscoelastic testing using ClotPro® for short-term outcome in patients with severe Covid-19 ARDS with or without ECMO therapy: a retrospective study

  Non-ECMO ECMO p
Age [years] 69 (63; 71) 61.5 (56; 65)  < 0.05
Body Mass Index [kg/m2] 27.8 (25.1; 31.1) 31 (26.2; 37.5) 0.226
SOFA Score [points] 11 (10;14) 11 (10; 13) 0.910
Charlson Comorbidity Index 4 (3; 7) 2 (2; 3)  < 0.05
Dosis of UFH [mg/h] 1400 (800; 1800) 1600 (1200; 1900) 0.238
LMWH [mg/24 h] 120 (100; 180) - -
Horovitz Quotient at ICU admission * [mmHG] 146 (114; 219) 160 (137; 189) 0.487
Lowest Horovitz Quotient during ICU stay * [mmHG] 52 (45; 67.5) 53 (37.5; 67.5) 0.848
Prophylactic Anticoagulation 9 (27%) 3 (14%) 0.195
Intermediate Anticoagulation 11 (33%) 15 (68%)  < 0.05
Any coagulation-associated Complication 19 (58%) 12 (55%) 0.824
BARC_2 2 (6%) 2 (9%) 0.528
BARC_3c 1 (3%) 1 (5%) 0.999
VTE/ATE at VET 14 (42%) 8 (36%) 0.653
ATE 2 (6%) 0 0.356
DVT 8 (24%) 7 (32%) 0.376
CAT 0 2 (9%) 0.156
PE 11 (33%) 6 (27%) 0.634
In-hospital Death 20 (61%) 10 (45%) 0.269
  1. ECMO Extracorporeal Membrane-Oxygenation, SOFA Sepsis-related organ failure assessment, UFH Unfractionated heparin, LMWH Low-molecular-weight heparin, ICU Intensive Care Unit, BARC Bleeding Academic Research Consortium, VTE Venous Thromboembolism, ATE Arterial Thromboembolism, VET Viscoelastic Testing, DVT Deep Vein Thrombosis, CAT Catheter-Associated Thrombosis, PE Pulmonary Embolismm, ARDS Acute Respiratory Distress Syndrome